Cannabis Community College Celebrates 4/20 With ‘Baby Got Bud’ Parody Video and Complimentary Courses

Cannabis Community College Celebrates 4/20 With ‘Baby Got Bud’ Parody Video and Complimentary Courses

April 20, 2023 Sam M 0

Cannabis Community College Celebrates 4/20 With ‘Baby Got Bud’ Parody Video and Complimentary CoursesCannabis Community College Celebrates 4/20 With ‘Baby Got Bud’ Parody Video and Complimentary Courses

In celebration of 4/20, Cannabis Community College is providing its entire curriculum free of charge for anyone interested in cannabis education or certification to work in the legal market.

Today, leading cannabis education provider Cannabis Community College celebrates the cannabis holiday 4/20 by releasing the parody Baby Got Bud video by “Sir Toke-A-Lot.” The organization is also giving away free cannabis courses and certifications on its platform until the month’s end to empower tomorrow’s industry professionals.

The entire curriculum is available free of charge by using the discount code 420FREE at checkout. 

“We wanted to do something fun and different this year to help celebrate the growth of our industry and thought it would be effective to educate through a parody and to offer free education,” said Christi McAdams, founder of Cannabis Community College. 

Cannabis Community College (CCC) provides state-specific education enabling students to work in any sector of the legal cannabis industry. Its platform covers state compliance, regulations, standard operating procedures, and much more. All of the courses are taught by leading industry experts who lend their insider knowledge on a variety of topics.

CCC also assists students looking for jobs through its paid intern project. The college has already trained and helped place over 2,000 students nationwide and anticipates boosting that number considerably this year. 

“Our industry offers unlimited growth potential to anyone with a good work ethic; therefore, we strive to educate and onboard as many people as we can reach,” McAdams added. “Our focus isn’t on making money — it’s on changing people’s lives.”

Depending on the response, CCC may extend its free course offer indefinitely through the college’s scholarship programs to guarantee quality cannabis education to anyone, regardless of financial ability.

For more information about Cannabis Community College, visit www.cannabiscommunitycollege.com

Contact Information:

Rachelle Gordon

Journalist

[email protected]

Andrea Zavala

Public Relations

[email protected]

(702) 844-9962

Original Source:

Cannabis Community College Celebrates 4/20 With ‘Baby Got Bud’ Parody Video and Complimentary Courses

The post Cannabis Community College Celebrates 4/20 With ‘Baby Got Bud’ Parody Video and Complimentary Courses first appeared on Enrose Magazine.

Tonic3 Obtains Patent for Augmented Reality Platform

Tonic3 Obtains Patent for Augmented Reality Platform

April 20, 2023 Sam M 0

Tonic3 Obtains Patent for Augmented Reality PlatformTonic3 Obtains Patent for Augmented Reality Platform

U.S. Patent and Trademark Office (USPTO) Granted Patent on March 25 for Tonic3’s ‘Augmented Reality (AR) Platform’

Tonic3 Obtains Patent for Augmented Reality Platform
Augmented Reality Management System

Image of Tonic3’s patented Augmented Reality Management System

Tonic3, a leading provider of Enterprise User Experience and Engineering Solutions, recently announced a milestone. On March 25, the U.S. Patent and Trademark Office (USPTO) granted a patent for its “Augmented Reality (AR) platform.”

The patent covers a unique method of processing augmented reality technology as a platform ecosystem, including specialized experience triggers and multi-device experience synchronization. 

This is Tonic3’s first patent, made possible through the work of its XR Labs, a specialized research and publishing team focused on providing thought leadership and best practices to the extended reality (XR) industry. XR refers to immersive technologies, including virtual reality (VR), augmented reality (AR), and mixed reality. AR is a set of technologies that allow users to visualize part of the real world through a technological device with graphical information added by the user.

“At our XR Labs, we focus on the end-user first by applying techniques and empirical models to create groundbreaking technology applications in augmented reality, virtual reality, artificial intelligence, and other related fields,” said Preston McCauley, Director of Innovation at Tonic3, about this recent and valuable achievement.

Tonic3 has been a leader in technology development for several years and works with clients from many industries. The patent grant reflects part of the company’s future as it combines UX expertise with cutting-edge technology and the ability to fully deliver solutions.

About Tonic3

Tonic3 has been dedicated to humanizing digital connections for over 25 years, through insight-driven solutions in Enterprise UX, Development, and now AR/VR. The company has 100 full-time team members in the United States and Latin America, working with diverse clients across multiple verticals, ranging from Fortune 100 to funded startups.

Tonic3’s XR Labs is a specialized research and publishing team dedicated to bringing thought leadership to the extended reality (XR) industry, as well as recognizing and establishing XR best practices. From neurological and physiological impacts to XR research methodologies and design and coding processes that help deliver real-world XR experiences, XR Labs aims to build and share a knowledge base that encourages the growth of a digitally connected XR future for people around the world.

For more information, please visit www.tonic3.com or follow company news on LinkedIn at https://www.linkedin.com/company/tonic3/.

Contact Information:

Joe Edwards

CEO

[email protected]

214.774.2390

Alejandra Sanchez

Head of Customer Success

[email protected]

214.774.2390

Original Source:

Tonic3 Obtains Patent for Augmented Reality Platform

The post Tonic3 Obtains Patent for Augmented Reality Platform first appeared on Enrose Magazine.

Form Bio Joins PacBio Compatible Program to Accelerate Gene Therapy Research From Data to Insights

Form Bio Joins PacBio Compatible Program to Accelerate Gene Therapy Research From Data to Insights

April 19, 2023 Sam M 0

Form Bio Joins PacBio Compatible Program to Accelerate Gene Therapy Research From Data to InsightsForm Bio Joins PacBio Compatible Program to Accelerate Gene Therapy Research From Data to Insights

Combination of PacBio’s HiFi Sequencing Capabilities and Form Bio’s Computational Platform and Solutions Helps Biopharma and Academic Researchers Innovate and Accelerates Gene Therapy Product Development

Form Bio, the provider of advanced computational life sciences technology, today announced it has joined the PacBio Compatible program. As part of the program, the Form Bio platform has been verified as compatible with PacBio’s HiFi sequencing solutions, empowering corporate and academic research teams with a dramatically streamlined path from HiFi read data to breakthrough insights.

In particular, AAV-based gene therapy can address the underlying genetic problems that cause disease and holds great promise to help improve human health. With the combination of Form Bio’s data analysis capabilities and PacBio’s sequencing solutions, scientists can enhance their understanding of the genetic components underlying disease and ultimately improve AAV gene therapies in their application to a vast spectrum of diseases.

PacBio is a developer of high-quality, highly accurate sequencing solutions, providing the advantage of being able to sequence entire, intact constructs with high accuracy. The ability to produce full length reads is important for AAV gene therapy discovery and for confirming the quality of these constructs.

By combining PacBio’s HiFi sequencing capabilities with Form Bio’s innovative computational platform and solutions, mutual customers can not only accelerate but also advance and enhance the quality of research that relies on full read data. In addition, the Form Bio platform includes access to an optimized AAV PacBio QC workflow for characterizing the quality of AAV vector manufacturing.

“We’re thrilled to team up with PacBio to help advance gene therapy discovery and development,” said Kent Wakeford, co-CEO for Form Bio. “This partnership brings together our technology and expertise to provide an ‘easy button’ for PacBio customers, who are looking to get the most out of their HiFi sequencing data but face practical constraints with bioinformatics or computational resources.”

“We share Form Bio’s vision to help scientists and gene therapy developers move the industry forward, making this partnership a natural fit,” said Jeff Eidel, chief commercial officer for PacBio. “Form Bio’s powerful platform, advanced AI-based solutions and uniquely strong combination of both life science and data science expertise all add tremendous value to how researchers utilize PacBio products and solutions.”

To learn more about how Form Bio and PacBio solutions work together, visit https://formbio.com/pacbio

About Form Bio

Form Bio is a cutting-edge research and discovery platform for individuals and enterprises in life sciences. With an accessible, comprehensive and collaborative platform, Form Bio empowers scientists to efficiently and effectively harness the proliferation of data and computing power that has transformed the science of discovery. Form offers end-to-end integration of the discovery process with intuitive and easy-to-use software applications, combined with an open and adaptable collaborative environment. For more information on Form Bio, visit www.formbio.com

Contact Information:

Maggie Whitney

Senior Public Relations Executive

[email protected]

2039571502

Alison Guzzio

Public Relations Director

[email protected]

4844593243

Original Source:

Form Bio Joins PacBio Compatible Program to Accelerate Gene Therapy Research From Data to Insights

Form Bio Joins PacBio Compatible Program to Accelerate Gene Therapy Research From Data to Insights

The post Form Bio Joins PacBio Compatible Program to Accelerate Gene Therapy Research From Data to Insights first appeared on Enrose Magazine.

Brightstar Therapeutics Secures Series A Financing to Propel Groundbreaking Treatment for Corneal Diseases; Appoints Chief Medical Officer and Chief Scientific Officer to Lead